insights_auto
Outlook: 20.6% bullish·30.9% bearish
Go to analysischevron_right
MRNA:NASDAQ
Moderna Inc
$197.00
arrow_upward
+0.26%(+0.52) 1D
$195.74
arrow_downward
-0.64% (-1.26)bedtimeAfter hours
Closed: Oct 8, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MRNA...
Open
$196.42
High
$199.92
Low
$192.71
Mkt. cap
78.65B
Avg. vol.
16.37M
Volume
0.00
52-wk high
$212.19
52-wk low
$22.29
EPS
-$7.98
Beta
1.09
Shares outstanding
399.24M
No. of employees
5K
Open
$196.42
High
$199.92
Low
$192.71
Mkt. cap
78.65B
Avg. vol.
16.37M
Volume
0.00
52-wk high
$212.19
52-wk low
$22.29
EPS
-$7.98
Beta
1.09
Shares outstanding
399.24M
No. of employees
5K
News stories
From web sources and news partners
AD HOC NEWS
·
8 hours ago
Moderna stock gains 0.01 percent after-hours to EUR 174.77 versus the Lang & Schwarz prior close
Zacks
·
16 hours ago
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
Yahoo Finance
·
17 hours ago
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
The Motley Fool
·
1 day ago
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
About Moderna Inc